SAB Biotherapeutics, Inc.: shareholders and insiders

SABSNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.81

November 20, 2026Market cap $253M

What Ploutos Investor adds for SAB Biotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Sep 18, 2026, from their own Form 4 filings.

2 Form 4s

Bought on the market

–

nobody

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

  • Sep 17, 2026Alexandra KropotovaCHIEF MEDICAL OFFICER
    Kind
  • Jun 25, 2026Alexandra KropotovaCHIEF MEDICAL OFFICER
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade.

Insiders and their shares

Every buy and sale by SABS's officers and directors from 2021 up to November 21, 2025, 5 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

10 Holders over 5%1 On a 13DAug 14, 2026 Latest filing
  • Vivo Opportunity Fund Holdings, L.P.with 3 more persons
    Share of class9.99%
  • Commodore Capital LPwith 3 more persons
    Share of class9.90%
  • RA Capital Management, L.P.with 3 more persons
    Share of class9.90%
  • Balyasny Asset Managementwith 4 more persons
    Share of class9.45%
  • Biotechnology Value Fund L Pwith 9 more persons
    Share of class9.10%
  • Caligan Partners LPwith 1 more person
    Share of class8.80%
  • Adage Capital Management, L.P.with 2 more persons
    Share of class8.38%
  • Perceptive Advisors LLCwith 2 more persons
    Share of class7.30%
  • Woodline Partners LP
    Share of class6.80%
  • Millennium Management LLCwith 2 more persons
    Share of class5.10%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • RA Capital Management, L.P.9.9%From the filing of Mar 11, 2026

    Item 4 of the Statement is hereby amended and supplemented as follows: Pursuant to the Letter Agreement, RA Capital recommended David Zaccardelli, Pharm.D, and Rita Jain, M.D. to serve as directors of the Issuer. On January 5, 2026, the Board of Directors (the "Board") of the Issuer, following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Drs. Zaccardelli and Jain to the Board, to serve as directors until the Issuer's 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified.

    From the filing of Mar 11, 2026
Fell to 5% or less (1)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • RTW Investments, LP3.20%Feb 17, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Millennium Mgmt (Englander)
    In the quarter+26%
  • Citadel Advisors (Griffin)
    In the quarter+102%
  • Renaissance Technologies
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 5.33% of its shares outstanding were held short, +11.9% since the report before.

Shares held short
4.80M
5.33%
Since the report before4.29M on Sep 30, 2026
+11.9%
6.9
693.0K
More days to cover thanof 4,578 US-listed companies with enough volume
77%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 261.4K
  • Nov 15, 2023: Shares held short 229.8K
  • Nov 30, 2023: Shares held short 233.7K
  • Dec 15, 2023: Shares held short 207.6K
  • Dec 29, 2023: Shares held short 178.9K
  • Jan 12, 2024: Shares held short 17.4K
  • Jan 31, 2024: Shares held short 33.2K
  • Feb 15, 2024: Shares held short 39.0K
  • Feb 29, 2024: Shares held short 24.5K
  • Mar 15, 2024: Shares held short 20.9K
  • Mar 28, 2024: Shares held short 28.9K
  • Apr 15, 2024: Shares held short 25.6K
  • Apr 30, 2024: Shares held short 22.5K
  • May 15, 2024: Shares held short 22.5K
  • May 31, 2024: Shares held short 33.9K
  • Jun 14, 2024: Shares held short 34.2K
  • Jun 28, 2024: Shares held short 31.8K
  • Jul 15, 2024: Shares held short 26.4K
  • Jul 31, 2024: Shares held short 28.5K
  • Aug 15, 2024: Shares held short 26.2K
  • Aug 30, 2024: Shares held short 34.6K
  • Sep 13, 2024: Shares held short 30.2K
  • Sep 30, 2024: Shares held short 41.5K
  • Oct 15, 2024: Shares held short 79.8K
  • Oct 31, 2024: Shares held short 58.8K
  • Nov 15, 2024: Shares held short 39.9K
  • Nov 29, 2024: Shares held short 98.9K
  • Dec 13, 2024: Shares held short 56.4K
  • Dec 31, 2024: Shares held short 36.5K
  • Jan 15, 2025: Shares held short 53.5K
  • Jan 31, 2025: Shares held short 118.4K
  • Feb 14, 2025: Shares held short 67.7K
  • Feb 28, 2025: Shares held short 125.0K
  • Mar 14, 2025: Shares held short 115.0K
  • Mar 31, 2025: Shares held short 92.7K
  • Apr 15, 2025: Shares held short 71.5K
  • Apr 30, 2025: Shares held short 99.9K
  • May 15, 2025: Shares held short 72.0K
  • May 30, 2025: Shares held short 36.8K
  • Jun 13, 2025: Shares held short 33.8K
  • Jun 30, 2025: Shares held short 21.3K
  • Jul 15, 2025: Shares held short 21.1K
  • Jul 31, 2025: Shares held short 745.6K
  • Aug 15, 2025: Shares held short 502.0K
  • Aug 29, 2025: Shares held short 440.5K
  • Sep 15, 2025: Shares held short 405.2K
  • Sep 30, 2025: Shares held short 497.5K
  • Oct 15, 2025: Shares held short 692.7K
  • Oct 31, 2025: Shares held short 697.0K
  • Nov 14, 2025: Shares held short 676.5K
  • Nov 28, 2025: Shares held short 702.3K
  • Dec 15, 2025: Shares held short 901.5K
  • Dec 31, 2025: Shares held short 1.45M
  • Jan 15, 2026: Shares held short 1.56M
  • Jan 30, 2026: Shares held short 1.95M
  • Feb 13, 2026: Shares held short 1.86M
  • Feb 27, 2026: Shares held short 1.61M
  • Mar 13, 2026: Shares held short 1.95M
  • Mar 31, 2026: Shares held short 2.50M
  • Apr 15, 2026: Shares held short 3.00M
  • Apr 30, 2026: Shares held short 2.42M
  • May 15, 2026: Shares held short 2.75M
  • May 29, 2026: Shares held short 2.64M
  • Jun 15, 2026: Shares held short 2.88M
  • Jun 30, 2026: Shares held short 3.77M
  • Jul 15, 2026: Shares held short 4.38M
  • Jul 31, 2026: Shares held short 4.66M
  • Aug 14, 2026: Shares held short 4.63M
  • Aug 31, 2026: Shares held short 4.12M
  • Sep 15, 2026: Shares held short 3.60M
  • Sep 30, 2026: Shares held short 4.29M
  • Oct 15, 2026: Shares held short 4.80M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading29.9% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 29.9% of the shares in the reported trades were short sales, against 69.6% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
29.9%
The 14 beforeOct 14, 2026 – Nov 2, 2026
69.6%
Change
-39.7 pts
Short sales a dayon average, of 445.1K shares
133.2K
More than atof 3,666 US-listed companies, same days
5%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 60.7%
  • Oct 15, 2026: Short sales 93.5%
  • Oct 16, 2026: Short sales 73.2%
  • Oct 19, 2026: Short sales 60.1%
  • Oct 20, 2026: Short sales 83.8%
  • Oct 21, 2026: Short sales 73.4%
  • Oct 22, 2026: Short sales 71.1%
  • Oct 23, 2026: Short sales 69%
  • Oct 26, 2026: Short sales 46.9%
  • Oct 27, 2026: Short sales 49.8%
  • Oct 28, 2026: Short sales 87.7%
  • Oct 29, 2026: Short sales 66.9%
  • Oct 30, 2026: Short sales 65.1%
  • Nov 2, 2026: Short sales 58.1%
  • Nov 3, 2026: Short sales 64.9%
  • Nov 4, 2026: Short sales 44.9%
  • Nov 5, 2026: Short sales 55.5%
  • Nov 6, 2026: Short sales 67.5%
  • Nov 9, 2026: Short sales 22.5%
  • Nov 10, 2026: Short sales 35.8%
  • Nov 11, 2026: Short sales 17.8%
  • Nov 12, 2026: Short sales 1.4%
  • Nov 13, 2026: Short sales 66.4%
  • Nov 16, 2026: Short sales 81.3%
  • Nov 17, 2026: Short sales 80.8%
  • Nov 18, 2026: Short sales 75.5%
  • Nov 19, 2026: Short sales 25.4%
  • Nov 20, 2026: Short sales 48.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

5.50M Insiders' shares10.79% Of the company
  • Eddie Joe SullivanChief Executive Officer
    Directly5.23M
  • Samuel J ReichExecutive Chairman
    Directly219.0K
  • Alexandra KropotovaCHIEF MEDICAL OFFICER
    Directly41.9K
  • Michael KingCHIEF FINANCIAL OFFICER
    Directly5,000

A lower bound: it counts only the 4 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

6 ETFs holding it0.04% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.04%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

6 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

87 Managers, Q2 2026$267M Value of their positions
  • Q3 2025: Managers 34
  • Q4 2025: Managers 48
  • Q1 2026: Managers 76
  • Q2 2026: Managers 87

Institutional investors by quarter

The fund managers holding SABS, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 87 managers held 68.40M shares, worth $267M. During the quarter 31 opened a position, 21 closed one, 24 added and 16 trimmed.

The largest holders, Q2 2026

  • Caligan Partners
    In the quarter
  • Vivo Capital
    In the quarter-36%
  • Perceptive Advisors
    In the quarter+3.0%
  • Adage Capital Partners Gp
    In the quarter+88%
  • Ra Capital Management
    In the quarter
  • Balyasny Asset Management
    In the quarter
  • BlackRock
    In the quarter×10.2
  • Vanguard Capital Management
    In the quarter+19%
  • Commodore Capital
    In the quarter-35%
  • Millennium Mgmt (Englander)
    In the quarter-9.4%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do SAB Biotherapeutics's filings show?

Who buys and sells is one part of SAB Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SABS's shareholders

Didn't find what you were looking for?

Ask us
Have SABS's insiders bought or sold?

From Jun 26, 2026 to Sep 18, 2026 SAB Biotherapeutics's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold SABS?

3 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $11M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.